Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Had been receiving a stable dose and regimen of an α-glucosidase inhibitor for the last 4 weeks or longer before the start of the screening phase (Week -8) and during the screening phase.~* Had a glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of the screening phase (Week -4).~* Had HbA1c differences within 10.0% at the start of the screening phase (Week -8) and 4 weeks after the start of the screening phase (Week -4) from the HbA1c value at the start of the screening phase.~* Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of the screening phase (Week -8).~Exclusion Criteria:~* Had received any antidiabetic drug other than α-glucosidase inhibitors within the last 4 weeks before the start of the screening phase (Week -8) or during the screening phase.

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Voglibose 0.2 mg TID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).